English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Physicians do not measure biomarkers simply to predict risk. Rather, they do so to better target therapy and improve the lives of their patients. Thus, when considering the use of any biomarker for cardiovascular risk prediction in primary prevention, thoughtful clinicians, and those writing guidelines should insist that two fundamental questions be answered affirmatively.First, is there clear evidence that the biomarker of interest predicts future cardiovascular events independent of other risk markers?And secondly, is there clear evidence that those identified by the biomarker of interest benefit from a therapy they otherwise would not have received?No imaging biomarker can answer these questions affirmatively, nor can a variety of plasma biomarkers such as lipoprotein(a) or triglycerides. As we will discuss below, the answer to both of these questions is clearly ‘yes’ for C-reactive protein as well as for cholesterol. Yet, while recent European Society of Cardiology guidelines for the prevention of heart disease strongly endorse cholesterol screening, those same guidelines are silent on C-reactive protein.1Inflammation is a fundamental component of atherosclerosis.2 For more than a decade, data from large-scale prospective cohorts in the USA and Europe have consistently indicated that the predictive value of the inflammatory biomarker C-reactive protein is at least as large as that of cholesterol.3,4 This observation is important since half of all heart attacks and strokes occur among those with average if not low cholesterol levels.That C-reactive protein and lipids are equal contributors to vascular risk has recently been confirmed in an elegant 2012 meta-analysis published in the New England Journal of Medicine by the Emerging Risk Factors Collaboration that analysed data from 38 prospective studies and included 166 596 men and women without prior disease.5 Specifically, for a prediction model that included age, smoking, systolic blood …

C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care